Comparative Pharmacology
Head-to-head clinical analysis: EVOCLIN versus FOAMCOAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOCLIN versus FOAMCOAT.
EVOCLIN vs FOAMCOAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
FOAMCOAT is a proprietary fibrin sealant containing human fibrinogen and thrombin. When applied topically, thrombin converts fibrinogen into fibrin monomers that polymerize into a stable clot. This forms a mechanical barrier and promotes hemostasis through the final step of the coagulation cascade.
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
FOAMCOAT is a topical hemostatic agent; standard adult dose is 1 to 2 mL applied directly to bleeding site, repeated as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing.
Terminal elimination half-life is 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%.
Primarily renal excretion of intact drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Category C
Category C
Topical Antibiotic
Topical Antibiotic